Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF, et al.
Archives of surgery (Chicago, Ill. : 1960). Date of publication 1994 Feb 1;volume 129(2):213-9.
1. Arch Surg. 1994 Feb;129(2):213-9.
A phase II study to evaluate recombinant platelet-derived growth factor-BB in the
treatment of stage 3 and 4 pressure ulcers.
Mustoe TA(1), Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar
CM, Pierce GF.
Author information:
(1)Division of Plastic and Reconstructive Surgery, Northwestern Medical School,
Chicago, Ill.
OBJECTIVE: To determine the efficacy of the daily topical application of
recombinant platelet-derived growth factor-BB (rPDGF-BB), a recognized vulnerary
agent, in the treatment of deep pressure ulcers.
DESIGN: Prospective, randomized, double-blind trial.
SETTING: Patients were treated in a nursing home or a hospital setting before
transfer to a nursing home.
PATIENTS: Eligibility criteria included a clean pressure ulcer that had been
adequately debrided and the absence of severe cardiac, pulmonary, or renal
conditions. The causes of the ulcers were not related to a venous or arterial
vascular disorder. The patients were elderly (mean age, 68 to 74 years).
INTERVENTIONS: After randomization, patients were given daily topical aqueous
rPDGF-BB (dosage, 100 or 300 micrograms/mL) or placebo and saline gauze dressings
were applied daily in addition to frequent turning.
MAIN OUTCOME MEASURE: Serial volume measurements of the healing wounds were taken
using alginate molds.
RESULTS: The ulcers of 41 patients were analyzed. At the end of 28 days, median
ulcer volumes had decreased to 83%, 29%, and 40% of the initial size in the
groups receiving placebo, rPDGF-BB, 100 micrograms/dL, and rPDGF-BB, 300
micrograms/mL, respectively. When adjusted for initial volume, ulcer volume after
28 days of treatment was smaller in the rPDGF-BB-treated groups compared with the
placebo group (analysis of covariance, P = .056). Ulcers in the two
rPDGF-BB-treated groups were significantly smaller in volume compared with those
in the placebo group, using a linear contrast procedure.
CONCLUSIONS: Data from this small trial suggest that local application of
rPDGF-BB may be of therapeutic benefit in accelerating the healing of chronic
pressure ulcers.
PMID: 8304833 [Indexed for MEDLINE]
